Health Economics & Outcomes Research (HEOR)
Analysis Group is distinguished by our understanding of health economics and outcomes. We collaborate with many clients to develop and implement HEOR strategies to support pharmaceutical products throughout their life cycles. Our expertise includes comprehensive research capabilities, defined by cutting-edge methodologies that draw on diverse data sources from U.S. and global markets. Our studies have involved diverse geographies, including Argentina, Australia, Brazil, Canada, China, Colombia, France, Germany, Finland, Israel, Japan, Mexico, Portugal, Saudi Arabia, Scotland, South Korea, Spain, Sweden, Taiwan, the U.K., and the United States.
We have developed different types of models to address clients’ needs, including budget impact models to assess the economic implications of new formulary cost-minimization, cost-utility, and cost-effectiveness to compare a client’s drugs to comparators, and simple cost calculators to evaluate the costs of treatments
and costs of adverse events.
Our interdisciplinary team includes numerous health care specialists across 11 offices worldwide, with advanced degrees and expertise in health economics, econometrics,
epidemiology, psychometrics, medicine, pharmacy, and health policy.
Areas of Expertise
- Burden-of-Illness Research
- Comparative Effectiveness Research
- Patient-Reported Outcomes
- Clinical Research & Study Design
- Personalized Medicine
- Rare Disease & Orphan Drug Research